IDEAYA initiates Phase 1/2 Part 2 monotherapy expansion for IDE892 in MTAP-deleted cancers

Reuters2026/07/27 10:01

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

IDEAYA initiated Part 2 monotherapy expansion in its Phase 1/2 study of IDE892 for MTAP-deleted pancreatic cancer, NSCLC.
Dose escalation cleared multiple cohorts; projected efficacious exposures reached with 24-hour EC90 target coverage; maximum tolerated dose not yet reached.
IDE892 positioned as a combination partner; escalation continues with IDE397 in MTAP NSCLC, PDAC; pan-RAS combination first-patient-in targeted H2 2026.
Company targets a MTAP/CDKN2A, KRAS, pancreatic cancer R&D Day in Q4 2026; CDKN2A program targets IND in H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607270600PR_NEWS_USPR_____SF11839) on July 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

IDEAYA initiates Phase 1/2 Part 2 monotherapy expansion for IDE892 in MTAP-deleted cancers

You may also like

Crypto prices